InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS) To broaden signal-finding activities for izicopan in ...
Compass’s completed all-stock merger is prompting investors to reprice the company as a newly structured platform rather than a pending transaction. The combined brokerage significantly expands scale, ...
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results